Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Bo40933
Previous Study | Return to List | Next Study

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03840200
Recruitment Status : Recruiting
First Posted : February 15, 2019
Last Update Posted : November 8, 2019
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Tracking Information
First Submitted Date  ICMJE February 11, 2019
First Posted Date  ICMJE February 15, 2019
Last Update Posted Date November 8, 2019
Actual Study Start Date  ICMJE June 11, 2019
Estimated Primary Completion Date September 24, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 11, 2019)
  • Percentage of Participants with Adverse Events [ Time Frame: Baseline up to approximately 3 years ]
  • Percentage of Participants with Dose-Limiting Toxicities (DLTs) that Determine the Maximum-Tolerated Dose (MTD) of the Ipatasertib and Rucaparib Combination [ Time Frame: Day -7 to Day 28 of Cycle 1; 1 cycle = 28 days ]
  • Percentage of Participants with Prostate-Specific Antigen (PSA) Response [ Time Frame: At screening (<=28 days of first dose), Day 1 of Cycle 1, 2, 3 and >= 4, at treatment discontinuation and post-treatment follow-up (1 cycle = 28 days; baseline up to approximately 3 years) ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03840200 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 11, 2019)
  • Percentage of Participants with Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1) [ Time Frame: At end of Cycle 2, 4, 6 and every 3 cycles thereafter up to progression (1 cycle = 28 days; baseline up to approximately 3 years) ]
  • Duration of Objective Response in Participants with Measurable Disease at Baseline, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: At end of Cycle 2, 4, 6 and every 3 cycles thereafter up to progression (1 cycle = 28 days; baseline up to approximately 3 years) ]
  • Radiographic Progression Free Survival, as Assessed by Prostate Cancer Working Group 3 Criteria [ Time Frame: At end of Cycle 2, 4, 6 and every 3 cycles thereafter up to radiographic progression (1 cycle = 28 days; baseline up to approximately 3 years) ]
  • Overall Survival in All Participants [ Time Frame: Baseline up to disease progression or death due to any cause whichever occurs first (up to approximately 3 years) ]
  • Plasma Concentration of Ipatasertib [ Time Frame: Day -7, 1, 15 of Cycle 1, Day 1, 15 of Cycle 2 (1 cyce = 28 days) ]
  • Plasma Concentration of Ipatasertib's Metabolite, G-037720 [ Time Frame: Day -7, 1, 15 of Cycle 1, Day 1, 15 of Cycle 2 (1 cycle = 28 days) ]
  • Plasma Concentration of Rucaparib [ Time Frame: Day -7, 1, 15 of Cycle 1, Day 1, 15 of Cycle 2 (1 cycle = 28 days) ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Official Title  ICMJE A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer
Brief Summary This is a study in participants with advanced breast, ovarian, or prostate cancer to investigate the dose, safety, pharmacokinetics, and preliminary efficacy of ipatasertib in combination with rucaparib. The study consists of two parts: a Dose-Escalation Phase (Part 1) in participants with previously treated advanced breast cancer, ovarian cancer, or prostate cancer and a Dose-Expansion Phase (Part 2) in participants with advanced prostate cancer who have had at least one line of prior therapy with second-generation androgen-receptor (AR)-targeted agents (e.g., abiraterone, enzalutamide, apalutamide).
Detailed Description

There are two parts in the study. A Dose-Escalation Phase (Part 1) in participants with previously treated advanced breast cancer, ovarian cancer, or prostate cancer. There will be a 7-day run-in period with ipatasertib alone prior to Cycle 1, Day 1. After the completion of the ipatasertib run-in period, participants will begin Cycle 1, Day 1 of the ipatasertib and rucaparib combination treatment. Each cycle has 28 days. Participants will be split into 4 cohorts: Dose Level 1 group - 300 mg ipatasertib once daily (QD) + 400 mg rucaparib twice daily (BID), Dose Level 2a: 300 mg ipatasertib QD + 600 mg rucaparib BID, Dose Level 2b: 400 mg ipatasertib QD + 400 mg rucaparib BID, Dose Level 3: 400 mg ipatasertib QD + 600 mg rucaparib BID

A Dose-Expansion Phase (Part 2) - The recommended dose identified in Part 1 (highest dose level of ipatasertib and rucaparib with an acceptable safety profile and less than one-third of participants experience a dose limiting toxicity) will be evaluated in participants with advanced prostate cancer who have had at least one line of prior therapy with second-generation androgen-receptor (AR)-targeted agents (e.g., abiraterone, enzalutamide, apalutamide).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Breast Cancer
  • Prostate Cancer
  • Ovarian Cancer
Intervention  ICMJE
  • Drug: Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib
    Ipatasertib, 300 mg administered PO QD for 7 days (run-in period prior to Cycle 1), then administer 300 mg PO QD for each cycle. Each cycle has 28 days. Doses are administered until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
    Other Name: RO5532961, GDC-0068
  • Drug: Part 1, Dose level 2b and dose level 3: Ipatasertib
    Ipatasertib, 400 mg administered PO QD for 7 days (run-in period prior to Cycle 1), then administer 400 mg PO QD for each cycle. One cycle has 28 days. Doses are administered until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
    Other Name: RO5532961, GDC-0068
  • Drug: Part 1, Dose Level 1 and Dose Level 2b: Rucaparib
    Rucaparib is administered 400 mg twice daily (BID) for each cycle. One cycle has 28 days. Doses are administered until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
    Other Name: CO-338
  • Drug: Part 1, Dose Level 2a and Dose Level 3: Rucaparib
    Rucaparib is administered 600 mg twice daily (BID) for each cycle. One cycle has 28 days. Doses are administered until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
    Other Name: CO-338
Study Arms  ICMJE
  • Experimental: Ipatasertib + Rucaparib
    A Dose-Escalation Phase (Part 1) in participants with previously treated advanced breast cancer, ovarian cancer, or prostate cancer. There will be a 7-day run-in period with ipatasertib alone prior to Cycle 1, Day 1. After the completion of the ipatasertib run-in period, participants will begin Cycle 1, Day 1 of the ipatasertib and rucaparib combination treatment. Each cycle has 28 days. Participants will be split into 4 cohorts: Dose Level 1 group - 300 mg ipatasertib once daily (QD) + 400 mg rucaparib twice daily (BID), Dose Level 2a: 300 mg ipatasertib QD + 600 mg rucaparib BID, Dose Level 2b: 400 mg ipatasertib QD + 400 mg rucaparib BID, Dose Level 3: 400 mg ipatasertib QD + 600 mg rucaparib BID
    Interventions:
    • Drug: Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib
    • Drug: Part 1, Dose level 2b and dose level 3: Ipatasertib
    • Drug: Part 1, Dose Level 1 and Dose Level 2b: Rucaparib
    • Drug: Part 1, Dose Level 2a and Dose Level 3: Rucaparib
  • Experimental: Part 2: Ipatasertib + Rucaparib
    A Dose-Expansion Phase (Part 2) - The recommended dose identified in Part 1 (highest dose level of ipatasertib and rucaparib with an acceptable safety profile and less than one-third of participants experience a dose limiting toxicity) will be evaluated in participants with advanced prostate cancer who have had at least one line of prior therapy with second-generation androgen-receptor (AR)-targeted agents (e.g., abiraterone, enzalutamide, apalutamide).
    Interventions:
    • Drug: Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib
    • Drug: Part 1, Dose level 2b and dose level 3: Ipatasertib
    • Drug: Part 1, Dose Level 1 and Dose Level 2b: Rucaparib
    • Drug: Part 1, Dose Level 2a and Dose Level 3: Rucaparib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 11, 2019)
54
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 5, 2021
Estimated Primary Completion Date September 24, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • A life expectancy of at least 3 months
  • Ability to swallow oral study drug
  • Have adequate organ and marrow function as confirmed by the laboratory values listed below, obtained within 28 days prior to the first dose of study treatment:
  • Bone marrow function assessments (without transfusion within 28 days prior to receipt of study treatment):

    1. ANC >= 1500 cells/uL (1.5 x 10^9/L) without granulocyte-colony stimulating factor support
    2. Platelet count >= 100.0 x 10^9/L
    3. Hemoglobin >= 9 g/dL (or 5.6 mmol/L)
  • Chemistry panel assessments:

    1. AST and ALT <= 1.5 x upper limit of normal (ULN); if liver metastases, <= 2.5 x ULN
    2. Bilirubin <= 1.5 x ULN (<= 3 x ULN if hyperbilirubinemia is due to Gilbert's syndrome)
    3. Serum albumin >= 3.0 g/dL
    4. Serum creatinine <= 1.5 x ULN or creatinine clearance >= 50 mL/min
    5. Fasting glucose <= 150 mg/dL and hemoglobin A1c <= 7.5%
  • Resolved or stabilized toxicities resulting from previous therapy to Grade 1 (except for alopecia and neuropathy).

Cancer-Related Inclusion Criteria

  • Have a histologically confirmed diagnosis of ovarian (Part 1 only), breast (Part 1 only) or prostate cancer (Part 1 and Part 2)
  • Disease must be either metastatic or locally advanced disease that cannot be treated with curative intent
  • For patients with ovarian cancer (Part 1 only):

    1. High-grade (2 or 3) serous or endometrioid or clear cell epithelial ovarian, fallopian tube, or primary peritoneal cancer (PPC)
    2. Must have received at least one prior platinum-based therapy and may have platinumsensitive disease (i.e., documented radiologic disease progression >= 6 months following the last dose of the platinum treatment administered) or platinum-resistant disease
    3. Have a CA-125 level that is > 2 x ULN
    4. Must have measurable disease by RECIST v1.1
  • For patients with breast cancer (Part 1 only): must be human epidermal growth factor receptor 2 negative (HER2-) (estrogen receptor [ER]/progesterone positive or negative):

    1. ER/progesterone-positive patients must have received and progressed on at least one endocrine therapy (adjuvant or metastatic)
    2. ER/progesterone-negative/HER2- (triple-negative breast cancer [TNBC]) patients must have received at least one prior line of chemotherapy for metastatic breast cancer
    3. Must not have received more than two prior lines of chemotherapy for metastatic breast cancer
    4. Must have measurable disease by RECIST v1.1

For patients with prostate cancer:

  1. Adenocarcinoma of the prostate without small cell or neuroendocrine features
  2. Surgical or medical castration with testosterone < 50 ng/dL (1.7 nM)
  3. Patients treated with luteinizing hormone-releasing hormone analogs must have initiated therapy at least 4 weeks prior to the first dose of study treatment and continue throughout the study treatment
  4. Progression of prostate cancer either via PSA progression (two rising PSA levels measured >= 1 week apart, with second result >= 1 ng/mL) or radiographic progression with or without PSA progression
  5. Must have received at least one prior line of second-generation androgen receptor targeted therapy (e.g., abiraterone, enzalutamide, apalutamide)
  6. Patients with prostate cancer must have either measurable disease by RECIST v1.1 or bone lesions by bone scan, or both.

    • Submission of a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 12 freshly cut, unstained, serial tumor slides from the most recently collected tumor tissue for central molecular analysis (retrospective NGS testing for HR and PI3K-AKT pathway status and for other protocol-mandated secondary and exploratory assessments). Cytologic or fine needle aspirate samples are not acceptable. Tumor tissue from bone metastases is not acceptable.
    • For men and women of child bearing potential: agreement to remain abstinent or use protocol defined contraceptive measures during the treatment period and for at least 28 days after the last dose of ipatasertib,or 6 months after the last dose of rucaparib, whichever occurs later

Exclusion Criteria:

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 28 days after the final dose of ipatasertib or 6 months after the final dose of rucaparib
  • Prior treatment with a PARP inhibitor, AKT inhibitor, or PI3K inhibitor
  • Treatment with investigational therapy within 14 days prior to initiation of study drug
  • Symptomatic and/or untreated CNS metastases
  • Uncontrolled tumor-related pain
  • Non-study-related minor surgical procedures <= 5 days or major (invasive) surgical procedure <=14 days prior to first dose of study treatment
  • Patients with active hepatitis C virus (HCV)
  • Hepatitis B virus (HBV) infection (chronic or acute), defined as having a positive hepatitis B surface antigen (HBsAg) test or a positive quantitative HBV DNA test
  • Known HIV infection
  • Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment
  • Malabsorption syndrome or other condition that would interfere with enteral absorption
  • Serious infection requiring antibiotics within 14 days of first dose of study treatment
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
  • Need for chronic corticosteroid therapy of >= 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressants for a chronic disease
  • History of another malignancy within 5 years prior to randomization, except for either adequately treated non-melanomatous carcinoma of the skin, adequately treated melanoma in situ, adequately treated non-muscle-invasive urothelial carcinoma of the bladder (Tis, Ta, and low-grade T1 tumors), or other malignancies where the patient has undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to have a recurrence rate of < 5% at 5 years.
  • History of clinically significant cardiovascular dysfunction
  • Presence of any other condition that may have increased the risk associated with study participation or may have interfered with the interpretation of study results, and, in the opinion of the investigator, would have made the patient inappropriate for entry into the study

Ipatasertib-Specific Exclusion Criteria:

  • Type 1 or Type 2 diabetes mellitus requiring insulin at study entry
  • History of inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis), active bowel inflammation (e.g., diverticulitis)
  • Treatment with strong CYP3A inhibitors or strong CYP3A inducers within 4 weeks or five elimination half-live of the inhibitors, whichever is longer, prior to initiation of study drug
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Reference Study ID Number: BO40933 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global.rochegenentechtrials@roche.com
Listed Location Countries  ICMJE Australia,   Italy,   Korea, Republic of,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03840200
Other Study ID Numbers  ICMJE BO40933
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Hoffmann-La Roche
Study Sponsor  ICMJE Hoffmann-La Roche
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Trials Hoffmann-La Roche
PRS Account Hoffmann-La Roche
Verification Date November 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP